Hi Rudra,

Price erosion is always a very debatable topic and except for the pharma companies, I doubt anyone else knows about it accurately (it’s an area where we should work on).
If you go through the article, it says ‘Currently there is a limited competition for the product and the company can conservatively garner sales of US $50-60 million in sales for the 50 mg capsules’ (would rather ignore what the journalists are writing and give more weightage to the analysts). The analyst is talking about 50 mg capsule while it is also availabe in 100 mg, 200 mg and 400 mg (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Generics&Mkt=1). I still dont know how to interpret it.
You will always find reports on negative reports on generics (may be propagated by the innovators themselves). Not exactly sure how serious they are about gCelebrex.

Hello drrakesh,

the newer patent was a mere extension sought by Pfizer. Refer this article for the full context of this.

Judge Allen invalidated the reissue patent for the same reason the Federal Circuit invalidated the original one — “double-patenting.” Pfizer had argued that, as part of the reissue, it had reclassified the patent in a way that made it eligible for a safe harbor that protects patents from invalidation on “double-patenting” grounds. But Judge Allen found that the reissuance process could not be used for that purpose, and the flaw was therefore “not correctable.”

Hi Anil,
IMHO the link below can provide us insight that supply is not a concern yet as stock exists after taking into account local supply and exports.

http://www.supima.com/view-reports/supply-and-use/

The winds are favouring the Indian Textile industry and also factories in China are lowering their production due to high overhead costs and hence demand for raw material would decrease in China. The excess raw material can then make way to India.

As per this http://www.piindustries.com/sites/default/files/As%20Demand%20for%20Faster_1.pdf PI works with Syngenta.

You can also find other names in there.

For its domestic input business, the company licenses and registers products it
considers to have major potential in India from Japanese players such as Kumiai, Mitsui and Nichino, and markets them on an exclusive basis. Additionally, PI works with multinationals that already have a presence in India, such as Bayer CropScience, Syngenta and BASF, and co-markets their products under the PI brand.